Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry is faced with steadily declining R&D efficiency which results in fewer drugs reaching the market despite increased investment. A major cause for this low efficiency is the failure of drug candidates in late-stage development owing to safety issues or previously undiscovered side-effects. We analyzed to what extent gene expression data can help to de-risk drug development in early phases by detecting the biological effects of compounds across disease areas, targets and scaffolds. For eight drug discovery projects within a global pharmaceutical company, gene expression data were informative and able to support go/no-go decisions. Our studies show that gene expression profiling can detect adverse effects of compounds, and is a valuable tool in early-stage drug discovery decision making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Cited by
DeepTox: toxicity prediction using deep learning
Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016) · Frontiers in Environmental Science · doi:10.3389/fenvs.2015.00080 · Cited by 1,081
“…2 February 2016 | Volume 3 | Article 80 based methods and requires deep insights into chemical and biological properties and processes (Verbist et al., 2015), such as interactions between molecules (e.g., ligand-target), reactions and enzymes involved, and metabolic modifications of…”
Self-citationA comprehensive evaluation of module detection methods for gene expression data
Saelens, W., Cannoodt, R., & Saeys, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-03424-4 · Cited by 311
Representing high throughput expression profiles via perturbation barcodes reveals compound targets
Filzen, T. M., Kutchukian, P. S., Hermes, J. D., Li, J., & Tudor, M. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005335 · Cited by 31
Compound Activity Prediction with Dose-Dependent Transcriptomic Profiles and Deep Learning
Godinez, W. J., Trifonov, V., Fang, B., Kuzu, G., Pei, L., Guiguemde, W. A., Martin, E. J., King, F. J., Jenkins, J. L., & Skewes-Cox, P. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01855 · Cited by 7
Metadata
- Authors
- Verbist, B., Klambauer, G., Vervoort, L., Talloen, W., Shkedy, Z., Thas, O., Bender, A., Göhlmann, H. W. H., & Hochreiter, S.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 20
- Issue
- 5
- Pages
- 505-513
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2007667104
- Cited by
- 96
- References
- 6
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project. https://app.cochat.ai/papers/10.1016/j.drudis.2014.12.014
- The paper
- Verbist, B., Klambauer, G., Vervoort, L., Talloen, W., Shkedy, Z., Thas, O., Bender, A., Göhlmann, H. W. H., & Hochreiter, S. (2015). Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2014.12.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.